VAP-cyclo: a short intensive regimen of chemotherapy for advanced breast cancer
Bramwell, V.H.; Howell, A.; Scarffe, H.; Crowther, D.; Sellwood, R.A.
Cancer Treatment Reports 66(11): 1999-2000
1982
ISSN/ISBN: 0361-5960 PMID: 6897207 Document Number: 193453
Document emailed within 1 workday
Related Documents
1995: Growth factor allows effective dose-intensive regimen in advanced breast cancer patients Oncology 9(7): 684Maneechawakajorn, J.; Suksuperm, J. 2014: Quality of life in advanced non-small cell lung cancer receiving chemotherapy of platinum combination in old versus new standard chemotherapy regimen Journal of the Medical Association of Thailand 97(Suppl 11): S69-S75
Nicolato, A. 1990: Intra-arterial regional chemotherapy and intensive loco-regional radiotherapy in the treatment of locally advanced cancer of the breast La Radiologia Medica 80(3): 347-351
Taguchi, T.; Sakai, K.; Terasawa, T.; Wada, H. 1986: Results of clinical trials with a CMitF (cyclophosphamide, mitoxantrone, and 5-fluorouracil) regimen versus a CAF (cyclophosphamide, adriamycin, and 5-fluorouracil) regimen in advanced/relapsed breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 13(9): 2820-2828
Stamatovic, L.; Susnjar, S.; Gavrilovic, D.; Minic, I.; Ursulovic, T.; Dzodic, R. 2018: The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients Journal of Buon: Official Journal of the Balkan Union of Oncology 23(5): 1273-1280
de Graaf, H.; Willemse, P.H.; Sleijfer, D.T.; de Vries, E.G.; Van der Graaf, W.T.; Beukema, J.; Mulder, N.H. 1994: Effective conditioning regimen for premenopausal patients with advanced breast cancer Anticancer Research 14(6b): 2799-2804
Chitapanarux, I.; Lorvidhaya, V.; Kamnerdsupaphon, P.; Tharavichitkul, E.; Trakultivakorn, H.; Somwangprasert, A.; Sumitsawan, S.; Srisukho, S.; Watcharachan, K.; Sukthomya, V. 2006: Gemcitabine plus cisplatin (GC): a salvage regimen for advanced breast cancer patients who have failed anthracycline and/or taxane therapy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 33(6): 761-766
Kinoshita, K.; Yonemura, Y.; Sawa, T.; Miyata, T.; Sakuma, H.; Matsuki, N.; Tanaka, S.; Fushida, S.; Fujimura, T.; Mok, Y.Jai.; Kim, B.Sik.; Lee, J.In.; Choi, D.Wook.; Song, Y.Jin.; Yang, D.Hyun.; Kwon, S.Joon.; Tanaka, M.; Miyazaki, I. 2003: 5-Fluorouracil, methotrexate, leucovorin, CDDP and epirubicin (FEPMTX): a wide-spectrum regimen of salvage chemotherapy for high-grade advanced gastric cancer Hepato-Gastroenterology 50(53): 1716-1719
Garewal, H.S. 1988: Mitomycin C in the chemotherapy of advanced breast cancer Seminars in Oncology 15(3 Suppl 4: 74-79
Cocconi, G.; De Lisi, V.; Mori, P.; Bozzetti, C. 1982: Estrogen receptors and response to chemotherapy in advanced breast cancer Tumori 68(1): 67-71
Aomatsu, N.; Kashiwagi, S.; Morisaki, T.; Ishihara, S.; Asano, Y.; Watanabe, M.; Noda, S.; Kawajiri, H.; Takashima, T.; Onoda, N.; Ishikawa, T.; Hirakawa, K. 2013: Usefulness of bevacizumab combination chemotherapy for advanced breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 40(12): 2393-2395
Kimura, M.; Koida, T.; Yanagita, Y. 2000: Weekly administration of paclitaxel for advanced or metastatic breast cancer--short-course premedications for outpatients Gan to Kagaku Ryoho. Cancer and ChemoTherapy 27(11): 1703-1708
Jönsson, P.E.; Malmberg, M.; Ericsson, M.; Ryden, S. 1991: Weekly dose adriamycin as first line chemotherapy in advanced breast cancer Anticancer Research 11(2): 877-879
Closon, M.T.; Verbeke, L.; Kains, J.P.; Tijtgat, J.; Schallier, D. 1995: Combination chemotherapy with carboplatin, cyclophosphamide and fluorouracil in advanced breast cancer Anticancer Research 15(2): 591-595
Kashiwagi, S.; Ishihara, S.; Asano, Y.; Kurata, K.; Tauchi, Y.; Tokumoto, M.; Morisaki, T.; Noda, S.; Kawajiri, H.; Takashima, T.; Onoda, N.; Hirakawa, K. 2014: Eribulin chemotherapy after taxane treatment in advanced metastatic breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(12): 1951-1953
Kiang, D.T.; Frenning, D.H.; Gay, J.; Goldman, A.I.; Kennedy, B.J. 1980: Estrogen receptor status and response to chemotherapy in advanced breast cancer Cancer 46(12 Suppl): 2814-2817
Razis, E.D.; Samonis, G.; Cook, P.; Beer, M.; Mittelman, A.; Lake, D.E.; Feldman, E.J.; Puccio, C.; Ahmed, T. 1994: TMJ: a well-tolerated high-dose regimen for the adjuvant chemotherapy of high risk breast cancer Journal of Medicine 25(3-4): 241-250
Abe, O.; Izuo, M.; Enomoto, K.; Kubo, K.; Koyama, H.; Sakai, K.; Terasawa, T.; Tominaga, T.; Nomura, Y. 1982: Combination chemotherapy of cyclophosphamide adriamycin and 5-fluorouracil (CAF) in advanced and recurrent breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 9(5): 866-873
Vici, P.; Foggi, P.; Colucci, G.; Capomolla, E.; Brandi, M.; Giotta, F.; Gebbia, N.; Di Lauro, L.; Valerio, M.Rosaria.; Paoletti, G.; Belli, F.; Pizza, C.; Giannarelli, D.; Lopez, M. 2005: Sequential docetaxel followed by epirubicin-vinorelbine as first-line chemotherapy in advanced breast cancer Anticancer Research 25(2b): 1309-1314
Pedrazzoli, P.; Zamagni, C.; Martoni, A.; Capotorto, A.M.; Da Prada, G.A.; Pavesi, L.; Preti, P.; Lelli, G.; Pannuti, F.; Robustelli della Cuna, G. 1994: Dose intensification of chemotherapy in advanced breast cancer: a feasibility phase II study Tumori 80(4): 273-275